| Literature DB >> 31847885 |
Mohaned Hameed1,2, Aleksandra Turkiewicz3, Martin Englund3,4, Lennart Jacobsson5, Meliha C Kapetanovic6,7.
Abstract
OBJECTIVE: To estimate the prevalence and incidence of non-gout crystal arthropathy in relation to socioeconomic factors in southern Sweden.Entities:
Keywords: Calcium pyrophosphate crystal deposition disease (CPPD); Incidence; Non-gout crystal arthropathy; Prevalence; Unspecified non-gout crystal deposition disease
Year: 2019 PMID: 31847885 PMCID: PMC6918617 DOI: 10.1186/s13075-019-2077-6
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Number of subjects diagnosed with non-gout crystal arthropathy (ICD10 M11) and relative distributions of subtypes for both prevalent cases (N = 2393) and incident cases (N = 2017) in 2014. Only the first (incident) diagnosis for 217 incident cases is listed. Diagnosis among (prevalent) cases-only the latest diagnosis included one diagnosis per person
| IC10 diagnostic codes | The numbers and distribution of subjects diagnosed with the various subcodes within M11 group among prevalent cases number (%) | The numbers and distribution of subjects diagnosed with the various subcodes within M11 group among incident cases number (%) | |
|---|---|---|---|
| All non-gout crystal arthropathies | 2393 (100%) | 217 (100%) | |
| Calcium pyrophosphate crystal deposition related arthropathy | M11.8 calcium pyrophosphate arthropathy | 216 (9.03%) | 26 (8.13%) |
| M11.8B in shoulder joint | 9 (0.38%) | 2 (0.63%) | |
| M11.8C in elbow joint | 14 (0.59%) | 3 (0.94%) | |
| M11.8D in wrist joint/hand | 61 (2.55%) | 20 (6.25%) | |
| M11.8F in hip joint | 11 (0.46%) | 2 (0.63%) | |
| M11.8G in knee joint | 352 (14.71%) | 48 (15.0%) | |
| M11.8H in ankle and foot | 31 (1.30%) | 7 (2.19%) | |
| M11.8X site unspecified | 12 (0.5%) | 10 (3.13%) | |
| Chondrocalcinosis | M11.1 familial chondrocalcinosis | 7 (0.29%) | 0 |
| M11.2 other chondrocalcinosis | 68 (2.84%) | 3 (0.94%) | |
| Hydroxyapatite crystal deposition disease | M11.0 hydroxyapatite deposition disease | 22 (0.92%) | 5 (1.56%) |
| Unspecified other non-gout arthropathies | M11.9 crystal arthropathy, unspecified | 289 (12.08%) | 36 (11.25%) |
| M11.9B crystal arthropathy, unspecified in shoulder joint | 23 (0.96%) | 2 (0.63%) | |
| M11.9C crystal arthropathy, unspecified in elbow joint | 18 (0.75%) | 5 (1.56%) | |
| M11.9D Crystal arthropathy, unspecified in wrist joint/ hand | 120 (5.01%) | 20 (6.25%) | |
| M11.9F crystal arthropathy, unspecified in hip joint | 33 (1.38%) | 2 (0.63%) | |
| M11.9G crystal arthropathy, unspecified in knee joint | 434 (18.14%) | 37 (11.56%) | |
| M11.9H crystal arthropathy, unspecified in ankle and foot | 199 (8.32%) | 12 (3.75%) | |
| M11.9X crystal arthropathy, unspecified with unspecified site | 9 (0.38%) | 5 (1.56%) | |
| M11- other crystal arthritis, unspecified | 465 (19.43%) | 75 (23.4%) |
Point prevalence and cumulative incidence of calcium pyrophosphate crystal arthropathy (CPPD) in Skåne, in 2014, age and sex stratified
| Prevalence | Cumulative incidence | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sex | Age group | Number of persons with diagnosis | Population ( | Prevalence/100,000 persons | 95% CI | Number of persons with diagnosis | Population ( | Cumulative incidence/100,000 persons | 95% CI |
| All | ≥ 18 | 869 | 1,022,545 | 85 | 80–91 | 81 | 1,012,218 | 8 | 6–10 |
| Women | All ≥ 18 | 383 | 519,302 | 74 | 67–82 | 31 | 514,766 | 6 | 4–8 |
| Women | 18–34 | 3 | 143,725 | 209 | 40–645 | 0 | 143,160 | 0 | 0–3 |
| Women | 35–44 | 8 | 83,016 | 964 | 451–1939 | 0 | 82,342 | 0 | 0–6 |
| Women | 45–54 | 20 | 83,240 | 2403 | 1531–3736 | 1 | 82,315 | 2 | 0–8 |
| Women | 55–64 | 46 | 73,596 | 6250 | 4668–8354 | 4 | 73,845 | 5 | 2–14 |
| Women | 65–74 | 73 | 70,995 | 10,282 | 8164–12,941 | 7 | 69,138 | 10 | 4–21 |
| Women | 75–84 | 108 | 41,956 | 25,741 | 21,306–31,088 | 12 | 41,258 | 29 | 16–51 |
| Women | 85+ | 125 | 22,774 | 54,887 | 46,054–65,388 | 7 | 22,708 | 31 | 14–65 |
| Men | ≥18 | 486 | 503,243 | 97 | 88–106 | 50 | 497,452 | 10 | 8–13 |
| Men | 18–34 | 3 | 145,893 | 206 | 39–635 | 0 | 145,102 | 0 | 0–3 |
| Men | 35–44 | 11 | 86,006 | 1279 | 683–2321 | 2 | 85,001 | 2 | 0–9 |
| Men | 45–54 | 33 | 84,971 | 3884 | 2747–5472 | 1 | 83,824 | 1 | 0–7 |
| Men | 55–64 | 89 | 72,781 | 12,229 | 9926–15,058 | 9 | 73,083 | 12 | 6–24 |
| Men | 65–74 | 154 | 68,254 | 22,563 | 19,262–26,424 | 18 | 66,377 | 27 | 17–43 |
| Men | 75–84 | 121 | 33,709 | 35,896 | 30,027–42,895 | 8 | 32,641 | 25 | 11–49 |
| Men | 85+ | 75 | 11,629 | 64,494 | 51,396–80,852 | 12 | 11,424 | 105 | 58–186 |
Point prevalence and cumulative incidence of other unspecified non-gout crystal arthropathy in Skåne in 2014, age and sex stratified
| Prevalence | Cumulative incidence | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sex | Age group | Number of persons with diagnosis | Population ( | Prevalence/100,000 persons | 95% CI | Number of persons with diagnosis | Population ( | Cumulative Incidence per 100,000 persons | 95% CI |
| All | ≥ 18 | 1662 | 1,022,545 | 163 | 155–171 | 158 | 1,011,458 | 16 | 13–18 |
| Women | All ≥ 18 | 734 | 519,302 | 141 | 131–152 | 71 | 514,434 | 8 | 6–10 |
| Women | 18–34 | 16 | 143,725 | 11 | 7–18 | 2 | 143,152 | 1 | 0–6 |
| Women | 35–44 | 18 | 83,016 | 22 | 13–35 | 1 | 82,328 | 1 | 0–8 |
| Women | 45–54 | 45 | 83,240 | 54 | 40–72 | 3 | 82,294 | 4 | 0–11 |
| Women | 55–64 | 107 | 73,596 | 145 | 120–175 | 12 | 73,788 | 16 | 9–29 |
| Women | 65–74 | 150 | 70,995 | 211 | 180–250 | 16 | 69,053 | 23 | 14–38 |
| Women | 75–84 | 215 | 41,956 | 512 | 448–586 | 24 | 41,168 | 58 | 39–87 |
| Women | 85+ | 183 | 22,774 | 804 | 695–930 | 13 | 22,651 | 57 | 32–99 |
| Men | All ≥ 18 | 928 | 503,243 | 184 | 173–197 | 87 | 497,024 | 18 | 14–22 |
| Men | 18–34 | 19 | 145,893 | 13 | 8–20 | 5 | 145,089 | 4 | 1–8 |
| Men | 35–44 | 35 | 86,006 | 41 | 29–57 | 4 | 84,974 | 5 | 1–13 |
| Men | 45–54 | 102 | 84,971 | 120 | 99–146 | 10 | 83,762 | 12 | 6–22 |
| Men | 55–64 | 165 | 72,781 | 227 | 195–246 | 14 | 73,008 | 19 | 11–33 |
| Men | 65–74 | 271 | 68,254 | 397 | 352–447 | 15 | 66,256 | 23 | 13–38 |
| Men | 75–84 | 212 | 33,709 | 629 | 550–719 | 21 | 32,549 | 65 | 42–99 |
| Men | 85+ | 124 | 11,629 | 1067 | 894–1270 | 18 | 11,386 | 158 | 89–252 |
Age- and sex-standardized prevalence of calcium pyrophosphate deposition crystal arthropathy (CPPD) and other non-gout crystal arthropathies and in relation to occupation and educational and income levels
| CPPD | Other non-gout crystal arthropathies | |
|---|---|---|
| Education | Prevalence (95% CI) | Prevalence (95% CI) |
| 0–9 years | 0.09 (0.08–0.10) | 0.19 (0.17–0.21) |
| 10–12 years | 0.09 (0.08–0.10) | 0.17 (0.15–0.18) |
| 13–14 years | 0.09 (0.07–0.11) | 0.14 (0.11–0.16) |
| 15+ years | 0.07 (0.05–0.09) | 0.13 (0.11–0.15) |
| Income | ||
| Lowest | 0.08 (0.07–0.10) | 0.14 (0.12–0.16) |
| Middle | 0.09 (0.08–0.10) | 0.17 (0.16–0.19) |
| Highest | 0.07(0.05–0.08) | 0.14 (0.12–0.17) |
| Occupation | ||
| White, high | 0.07 (0.06–0.09) | 0.14 (0.12–0.15) |
| White, low | 0.07 (0.06–0.09) | 0.16 (0.14–0.18) |
| Blue, high | 0.14 (0.10–0.17) | 0.19 (0.15–0.23) |
| Blue, low | 0.09 (0.07–0.11) | 0.17 (0.15–0.19) |